Address And Details

P.O.Box 8528 , Boston, MA 02266
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

The Fund seeks high total return with a shift to current income and some capital appreciation over time as the Fund approaches and passes the target retirement date. The JPMorgan SmartRetirement Blend 2025 Fund is a fund of funds that invests in other mutual funds and exchange traded funds (ETFs) within the same group of investment companies (J.P. Morgan Funds) and, for the limited purposes described below, also invests in market cap weighted index ETFs that are managed by unaffiliated investment advisers (unaffiliated passive ETFs) (collectively with the J.P. Morgan Funds, the underlying funds). The Fund also invests directly in securities and other financial instruments. The Fund is generally intended for investors expecting to retire around the year 2025 (the target retirement year). Blend in the Fund s name means that the Fund s adviser, J.P. Morgan Investment Management Inc. (JPMIM or the Adviser), uses underlying funds and strategies that attempt to replicate performance of various indexes as well as actively-managed underlying funds and strategies. The Fund is designed to provide exposure to a variety of asset classes through investments in underlying funds, securities and other financial instruments, and over time the Fund s asset allocation strategy will change.

Net Asset Value

as of 6:43 PM ET 09/17/2021

Performance

  • 1 Week
  • -0.36%
  • 1 Month
  • +0.32%
  • 3 Months
  • +0.82%
  • 1 Yr Return
  • +11.92%
  • 5 Yr Return
  • +31.66%

Equity Sector Breakdown

Finance 74.52%
ConsumerDurables n/a
Energy n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Other 74.52%
Stocks 25.48%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 72.12 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -1.17 -1.24 n/a
Beta 0.56 0.56 n/a
R Squared 0.91 0.89 n/a
Std Deviation 10.91 8.84 n/a
Sharpe Ratio 0.82 0.95 n/a

Purchase Information

as of 6:44 PM ET 09/16/2021
Minimum Initial $0
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +16.05%
  • +21.35%
+16.05% +21.35%
3 Year
  • +9.43%
  • +9.78%
+9.43% +9.78%
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +8.71%
  • +8.67%
+8.71% +8.67%

Top 10 Holdings

Symbol Company Name % Of Assets
JSDSX JPMORGAN SH DUR CORE PLUS FD 7.64%
JAGG JPMORGAN US AGGREGATE BD ETF 5.67%
JVAL JPMORGAN US VALUE FACTOR ETF 4.90%
EMRSX JPMORGAN EM MKT RES ENH EQ FD 4.77%
JPHY JPMORGAN HI YLD RES ENH ETF 3.18%
JRBSX JPMORGAN INFL MANAGED BOND FD 3.03%
BBMC JPMORGAN BETA BLDRS US MID CA 2.95%
BBRE JPMORGAN BETABLDRS MSCI US RE 2.94%
OHYFX JPMORGAN HIGH YIELD BOND FD 2.53%
BBIN JPMORGAN BETABUILDERS INTL EQ 14.42%

Recent Articles from TheStreet

Chinese Investors Mock Asset Managers And Offer Advice On Stock Picks For Cautious Approach To Renewables Sector

Stocks May Drop 20% as Stimulus Eases, Growth Slows: Morgan Stanley

Stocks could drop 20% as fiscal stimulus is withdrawn and economic growth slows, a Morgan Stanley strategist says.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Stock Rises on Progress With Breast-Cancer Treatment

AstraZeneca's breast-cancer treatment reduced the risk of disease progression or death by 72% vs. a currently approved treatment.

Cryptocurrency Lead

Cryptocurrency Price Check: Bitcoin Tumbles on Evergrande Woes

Bitcoin and other cryptocurrencies are battered as China Evergrande Group struggles with bond obligations.

China Aims To Strengthen Its Semiconductor Supply Chain With New Standards Group That Includes Huawei, SMIC

Brooks Automation Stock Jumps on Plan to Sell Chip Solutions Unit for $3B

Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.

DR Horton, Verizon, HCA Holdings Top Analysts' Actions Monday

DR Horton Trims 2021 Sales Forecast Amid Supply Chain Disruptions

DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.

11. Colgate-Palmolive

Colgate-Palmolive Underappreciated, Deutsche Bank Says, Lifting to Buy

Colgate-Palmolive stock was upgraded to buy with an $86 price target at Deutsche Bank.

Watch Jim Cramer Live 9/20

Video: Jim Cramer on the Market Selloff, Evergrande, Debt Ceiling, Fed, Pfizer

Jim Cramer discusses the market selloff, Evergrande, debt ceiling talks, the upcoming Federal Reserve meeting, Pfizer and more in his latest video interview with TheStreet.

Wynn Lead

Wynn Resorts 'Worth Risk' of Macau Restrictions, Morgan Stanley Says

Wynn Resorts faces regulatory uncertainty in Macau, but Morgan Stanley says the casino operator is still 'worth the risk.'

Chinese Tesla Challenger Xpeng Prices Its P5 Sedan From US$24,700 After Subsidies As Battle For EV Buyers Intensifies

Tesla Wider Self-Driving Effort Reportedly Opposed by NTSB Chief

Tesla wants to expand its autonomous-driving effort to help cars make their way through cities, not just highways.

BioNTech and Pfizer's mRNA-based vaccine candidate BNT162b2 has proven to be more than 90 per cent effective in preventing Covid-19 infections. Photo: Reuters

Premarket Movers Monday - Pfizer, Netflix, Li Auto, AstraZeneca

Stocks moving in premarket trading Monday include Pfizer, Netflix, Li Auto, AstraZeneca and Bank of America.